期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 62, 期 25, 页码 D100-D108出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2013.10.033
关键词
clinical trials; heart failure; pulmonary hypertension; pulmonary vascular disease
资金
- Actelion
- Bayer Schering
- GlaxoSmithKline
- Bayer
- Pfizer
- Novartis
- Aires Pharmaceuticals
- GenenTech
- United Therapeutics
- Eli Lilly and Company
- Bayer-Schering
Pulmonary hypertension (PH), a common complication of left heart diseases (LHD), negatively impacts symptoms, exercise capacity, and outcome. Although the true prevalence of PH-LHD is unknown, a subset of patients might present significant PH that cannot be explained by a passive increase in left-sided filling pressures. The term out-of-proportion PH has been used to identify that population without a clear definition, which has been found less than ideal and created confusion. We propose a change in terminology and a new definition of PH due to LHD. We suggest to abandon out-of-proportion PH and to distinguish isolated post-capillary PH from post-capillary PH with a pre-capillary component on the basis of the pressure difference between diastolic pulmonary artery pressure and pulmonary artery wedge pressure. Although there is no validated treatment for PH-LHD, we provide insights into management and discuss completed and randomized trials in this condition. Finally, we provide recommendations for future clinical trials to establish safety and efficacy of novel compounds to target this area of unmet medical need. (C) 2013 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据